Immune checkpoint inhibition in the treatment of early stage triple negative breast cancer: 2021 update()

There is an emerging body of evidence regarding the use of immunotherapy in early-stage triple negative breast cancer (TNBC), with the recent publication of several phase III and randomised phase II studies examining the role of immune checkpoint inhibitors (ICI) in the neoadjuvant setting in combin...

Descripción completa

Detalles Bibliográficos
Autores principales: Brown, Lauren C., Loi, Sherene
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9097806/
https://www.ncbi.nlm.nih.gov/pubmed/34996667
http://dx.doi.org/10.1016/j.breast.2021.12.018

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9097806/
https://www.ncbi.nlm.nih.gov/pubmed/34996667
http://dx.doi.org/10.1016/j.breast.2021.12.018

Ejemplares similares